Researchers at Mount Sinai have identified a unique neuron type that could explain vulnerability in Parkinson’s disease and thus help unravel the neuronal complexity of this disorder – hopefully leading to more precise and effective therapies. The findings, published in Science Advances on Jan. 10, 2024, provide new insights into the genetic causes and changes occurring in substantia nigra during PD pathogenesis. Read More
Huazhong University of Science and Technology and affiliated organizations have explored the role of microRNA-218-5p (miR-218-5p) in Parkinson’s disease (PD). Read More
Cellectar Biosciences Inc. has released promising preclinical data for its proprietary novel α-emitting phospholipid radiotherapeutic conjugate, CLR-121225 (225Ac-CLR-121225), an actinium-labeled phospholipid ether, in refractory pancreatic cancer mouse xenograft models. Read More
Coya Therapeutics Inc. intends to expand proposed indications for COYA-302 beyond amyotrophic lateral sclerosis (ALS) to include frontotemporal dementia (FTD) and Parkinson’s disease. Read More
SUMOylation is a post-translational modification implicated in DNA damage repair that has been linked to the lack of efficacy of some therapies commonly used for the treatment of leukemia. Read More
N4 Pharma plc’s subsidiary Nanogenics Ltd. has signed a contract to start the formulation and sequence selection work to prepare its ECP-105 product for testing in preclinical studies. Read More
The stress-responsive protein PPP1R15A (protein phosphatase 1, regulatory subunit 15 A) promotes the unfolded protein response and restores protein homeostasis. Read More
E-Therapeutics plc has offered a pipeline update, following the nomination of novel target genes, which have yielded promising results in preclinical studies. Read More
Biogen Inc. has synthesized non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of cancer, autoimmune disease, cardiovascular disorders, fibrosis, inflammatory disorders, liver diseases, pain and neurodegeneration, among others. Read More
Researchers at Guangzhou Salustier Biosciences Co. Ltd. and Jinan University (Guangdong) have identified selenium-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Aruna Bio Inc. has gained FDA clearance for its IND application for AB-126, enabling initiation of a phase Ib/IIa trial in acute ischemic stroke. Read More
Tempest Therapeutics Inc. has divulged three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer. Read More
Solid Biosciences Inc.’s SGT-003 has been granted orphan drug designation by the FDA. The company’s next-generation Duchenne muscular dystrophy gene therapy candidate was also granted fast track designation last month. Read More
Presage Biosciences Inc. has announced that the FDA has issued a study may proceed notification for testing a pre-GMP drug candidate with the company’s Comparative In Vivo Oncology (CIVO) platform. Owned by Pure Biologics, the drug candidate, PBA-0405, is a ROR1-targeting compound that has been engineered to induce tumor cell killing by cytotoxic immune cells. Read More
The Cleveland Clinic Foundation has described 3-β-hydroxysteroid dehydrogenase/δ5-->4-isomerase type 1 (3β-HSD I) inhibitors reported to be useful for the treatment of cancer. Read More
